This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Deaths Raise Safety Concerns Around Gene Therapy
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Deaths Raise Safety Concerns Around Gene Therapy
Business

Deaths Raise Safety Concerns Around Gene Therapy

Editorial Board Published October 1, 2021
Share
Deaths Raise Safety Concerns Around Gene Therapy
SHARE

Safety scares, including deaths of several young study subjects, have set back efforts to bring more gene therapies to market, clouding one of biotech’s most promising technologies and hottest sectors.

Contents
SHARE YOUR THOUGHTSThe Food and Drug Administration brought outside experts to a two-day public meeting to talk about how to address the potentially serious side effects associated with gene therapies.

Gene therapy, which replaces defective genes, promises to deliver one-time treatment for inherited diseases. Two treatments are approved for use, while dozens are in development.

In September, however, a young boy with a rare neuromuscular disease died after receiving a gene therapy in a clinical trial run by Japan’s Astellas Pharma Inc., ALPMY 0.61% and regulators halted a BioMarin Pharmaceutical Inc. BMRN -0.17% gene-therapy study after discovering cancer in mice that received the treatment.

SHARE YOUR THOUGHTS

What do you make of recent gene-therapy safety scares? Join the conversation below.

The Astellas-study death came after the trial was allowed to resume following the previous deaths of three boys treated with the same therapy.

The Food and Drug Administration held a two-day public meeting in September with outside experts to discuss how to manage the potentially serious side effects associated with gene therapies.

“Investor sentiment is probably at all-time lows for gene therapy,” said Luca Issi, senior biotechnology analyst at RBC Capital Markets. A few years ago, “the skies were blue, and now that is not the case.”

BioMarin’s share price fell 8.4% on the day after announcing the study pause, shedding $1.3 billion of its market value. Astellas shares fell 2% in Tokyo on the day following its disclosure of the patient death.

Across nearly 30 publicly traded gene-therapy developers, share prices have declined by an average of 25.6% so far in 2021, compared with a 6.9% rise in the Nasdaq Biotechnology Index and a 14.7% increase in the S&P 500.

Some gene-therapy researchers, however, say the spate of negative headlines is a symptom of the field’s success, which has led to an increase in gene-therapy treatments being tested in patients.

The Food and Drug Administration brought outside experts to a two-day public meeting to talk about how to address the potentially serious side effects associated with gene therapies.

Photo: jim lo scalzo/Shutterstock

“One of the reasons you’re hearing about all these [setbacks] is that the scale of these trials is going up exponentially because the therapies are all working so well,” says Nicole Paulk, assistant professor of biochemistry and biophysics at the University of California, San Francisco. “With that increase in numbers, there will be increases in growing pains.”

Gene therapy aims to treat diseases such as hemophilia and certain forms of muscular dystrophy by providing working copies of the genes that are defective or missing in people with inherited diseases. Typically, the new gene is carried inside a harmless virus (injected into the patient), which acts as a vessel to insert healthy DNA into cells.

Since 2015, 30 gene-therapy companies have gone public in initial-public offerings, raising $4.8 billion, according to data from Piper Sandler. More than 30 gene-therapy developers and suppliers have been acquired in deals valued at up to $43.5 billion since 2016, according to Piper.

Most gene therapies first pass through the liver before they can get to their intended cell targets, and it has long been known that high doses can cause liver damage. Researchers at the National Institutes of Health and elsewhere have in recent years also found a potential long-term risk for cancer in mice and dogs treated with gene therapies.

The risk of cancer resulting from gene therapies like the kind that BioMarin is developing has so far been seen only in animal studies, which aren’t always good proxies for how drugs will act in humans, said Henry Fuchs, president of world-wide research and development at BioMarin.

“Liver cancer as a result of gene therapy has never been observed in a human, and so at this point it remains a theoretical concern, not an observed risk,” Dr. Fuchs said.

BioMarin faced an even bigger setback last year when the FDA unexpectedly refused to approve BioMarin’s gene therapy for the bleeding disorder hemophilia, saying it wanted more detailed, long-term data before allowing the therapy on the market. “That surprise was a year-long setback,” Dr. Fuchs said.

BioMarin expects in the coming months to have two years of study data that the FDA requested and to file for approval in 2022, Dr. Fuchs said. The company has said available data indicate the therapy is effective for at least five years, but won’t be a lifetime cure.

Scientists have been working for decades to make gene therapy a reality, tantalized by the allure of curing inherited diseases such as cystic fibrosis by providing patients with functional copies of their defective genes.

More than 20 years ago, a single gene-therapy study death all but halted the research in its tracks. In 1999, a mostly healthy 18-year-old named Jesse Gelsinger died of multi-organ failure after receiving an experimental gene therapy for a rare liver disease.

In the aftermath, some large companies and academic researchers abandoned the research, and venture-capital funding dried up. The research that continued mostly ended in failure.

Over the past decade, however, the field made a comeback. The FDA approved the first gene-therapy product in 2017, clearing the use of Luxturna to treat an inherited type of vision-loss affecting up to 3,000 people in the U.S. In 2019, the regulator cleared Zolgensma to treat a muscle-wasting disease that affects as many as 500 babies born in the U.S. each year.

The lucrative market for rare-disease treatments, in which companies can charge high prices for small patient populations, helped trigger a wave of deal-making for gene-therapy makers. In 2018, Novartis AG had acquired Zolgensma-maker AveXis for $8.7 billion. The following year, Roche Holding AG agreed to buy Spark Therapeutics, developer of Luxturna, for $4.8 billion.

Also in 2019, Astellas paid $3 billion to acquire San Francisco-based Audentes Therapeutics Inc., developer of gene therapy for X-Linked myotubular myopathy, an often-fatal rare disease in which muscle weakness prevents normal bone development in babies, leading to difficulties breathing and swallowing.

Last year, researchers reported preliminary clinical trial data showing that many of the young boys treated with the Astellas therapy, code-named AT132, had rapid improvements in motor functions such as crawling and walking and their ability to breathe without ventilators.

Yet since the summer of 2020, four boys have died in the Astellas study of children younger than five years after developing liver dysfunction in the weeks after treatment.

Astellas researchers are still investigating the latest patient death in their gene-therapy study, but think that certain X-Linked myotubular myopathy patients are particularly susceptible to liver damage because of their underlying disease and that there is no evidence that an immune reaction to the virus delivering the healthy gene is causing the problem, said Nathan Bachtell, head of Astellas Gene Therapies.

The company hopes to find a way to safely restart the clinical trial, possibly by excluding enrollment of patients with a high risk of liver dysfunction, Dr. Bachtell said.

Write to Joseph Walker at [email protected]

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article Democrats Delay Vote on  Trillion Infrastructure Bill Democrats Delay Vote on $1 Trillion Infrastructure Bill
Next Article As Selling Luxury in China Gets Tougher, Buy American As Selling Luxury in China Gets Tougher, Buy American

Editor's Pick

Jordan Peterson Hospitalized, ‘Close to Loss of life’ Amid Weird Eating regimen, ‘A long time of Mould Publicity,’ Daughter Says

Jordan Peterson Hospitalized, ‘Close to Loss of life’ Amid Weird Eating regimen, ‘A long time of Mould Publicity,’ Daughter Says

Studying Time: 3 minutes Based on the most recent replace from his daughter, writer and psychologist Jordan Peterson is coping…

By Editorial Board 5 Min Read
Nicole Kidman Was ‘Blindsided’ By Keith City Affair, Blames Blake Shelton For Holding Secret: Report
Nicole Kidman Was ‘Blindsided’ By Keith City Affair, Blames Blake Shelton For Holding Secret: Report

Studying Time: 3 minutes For starters, insiders now declare that City already…

4 Min Read
Maggie Baugh: Every part We Know About Keith City’s Rumored New Girlfriend
Maggie Baugh: Every part We Know About Keith City’s Rumored New Girlfriend

Studying Time: 3 minutes Is Keith City hooking up together with his…

4 Min Read

Oponion

Trying to purchase your first residence? These markets are your finest guess in 2025

Trying to purchase your first residence? These markets are your finest guess in 2025

 The Claman Countdown panelists Dolly Lenz and Jenny Lenz analyze…

January 13, 2025

Jury urged to make R. Kelly pay for his alleged sex crimes

NEW YORK (AP) – With the…

September 23, 2021

San Jose Chamber of Commerce kicking off new 12 months with sports-themed occasion

Hear up, sports activities followers. The…

January 11, 2025

Prince Harry ‘Urged to Depart US’ After Decide Orders Launch of Immigration Paperwork

Studying Time: 3 minutes In his…

March 18, 2025

Faculty Soccer Playoff preview: Clemson’s win units up controversy with Alabama, SMU dueling for the ultimate spot

Clemson grew to become the fifth…

December 8, 2024

You Might Also Like

Russia for Business: Experts Who Help Drive Decisions
BusinessTrending

Russia for Business: Experts Who Help Drive Decisions

Amid sanctions and the restructuring of global supply chains, understanding the logic behind Russia’s actions has become a practical necessity…

4 Min Read
The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40
BusinessTrending

The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40

Across the nation, a quiet but powerful workforce shift is underway. Increasingly, women over 40 are seeking side hustles to…

4 Min Read
Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution
Business

Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution

At a time when billions of linked objects are reshaping industries, Thales has achieved a vital safety certification for its…

4 Min Read
Soracom IoT Platform Achieves SOC 2 Kind 2 Compliance for Safety, Availability, and Confidentiality
Business

Soracom IoT Platform Achieves SOC 2 Kind 2 Compliance for Safety, Availability, and Confidentiality

Soracom, Inc., right now introduced that it has efficiently achieved System and Group Controls (SOC) 2 Kind 2 compliance, reinforcing…

2 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?